Short answer
DiaMedica Therapeutics Inc. (DMAC) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$10M
- −30.3% YoY
- EPS (diluted)
- −$0.19
- −5.6% YoY
Source: XBRL data from the DiaMedica Therapeutics Inc. (DMAC) Q1 2026 10-Q on SEC EDGAR. USD.
DiaMedica Therapeutics Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales, commercial approval unavailable
- Net loss $10.0M vs $7.7M YoY; operating margin figures not disclosed
- R&D expenses $8.0M vs $5.7M, driven by ReMEDy2 expansion and PE testing
- Cash, equivalents and marketable securities $51.3M vs $59.9M at December 31, 2025
- Operating cash use $9.1M vs $7.1M; management expects funding for at least 12 months
- ReMEDy2 enrollment slower than expected; interim analysis estimated in fourth quarter 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward risks remain applicable to DiaMedica’s business, financial condition, and results
- Unknown or currently immaterial risks could impair future operations and financial condition
- No new trading-arrangement compliance risk; no director or officer adoptions or terminations during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other DiaMedica Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.